Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial

详细信息    查看全文

• 作者：Vidal Essebag ; MD ; PhD^a ; ^b ; ^{vidal.essebag@mcgill.ca" class="auth_mail" title="E-mail the corresponding author} ; Jeff S. Healey ; MD^c ; Felix Ayala-Paredes ; MD^d ; Eli Kalfon ; MD^a ; ^e ; Benoit Coutu ; MD^f ; Pablo Nery ; MD^g ; Atul Verma ; MD^h ; John Sapp ; MDⁱ ; Francois Philippon ; MD^j ; Roopinder K. Sandhu ; MD ; MPH^k ; Doug Coyle ; PhD^l ; John Eikelboom ; MD^c ; George Wells ; PhD^g ; David H. Birnie ; MD^g
• 刊名：American Heart Journal
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：173
• 期：Complete
• 页码：102-107
• 全文大小：191 K

文摘

Patients who require perioperative anticoagulation during cardiac implantable electronic device surgery are at increased risk for bleeding complications. The BRUISE CONTROL trial demonstrated that continuing warfarin was safer than heparin bridging, reducing the incidence of clinically significant pocket hematoma. Novel oral anticoagulants are being increasingly prescribed in place of warfarin. The best perioperative management of these new anticoagulants is unknown.

Methods/Design

A randomized controlled trial to investigate whether a strategy of continued vs interrupted novel oral anticoagulant (dabigatran, rivaroxaban, or apixaban) at the time of device surgery, in patients with moderate to high risk of arterial thromboembolic events, reduces the incidence of clinically significant hematoma (defined as a hematoma requiring reoperation and/or resulting in prolongation of hospitalization, and/or requiring interruption of anticoagulation). The secondary outcomes include components of the primary outcome, composite of all other major perioperative bleeding events, thromboembolic events, all-cause mortality, cost-effectiveness, patient quality of life, perioperative pain, and satisfaction. Planned analyses include descriptive statistics of all baseline variables. For the primary outcome, interrupted vs continued novel oral anticoagulant arms will be compared using the χ² test. If any clinically significant differences are identified, a logistic regression analysis will be conducted. Quality of life will be assessed using EuroQol-5D, and perioperative pain using a visual analog scale.

Discussion

BRUISE CONTROL-2 is a randomized trial evaluating the best strategy to manage novel oral anticoagulants at the time of device surgery. We hypothesize that device surgery can be performed safely without interruption of these medications.